Termination by Roche. In the event that Roche has exercised its First Option or its Second Option for a Compound, as applicable, and ROCHE decides to stop development or commercialisation of Compound (s) or Products for any reason, ROCHE may terminate this Agreement in its entirety or on a country-by country or Product-by Product basis at any time with six (6) months prior written notice, provided that ROCHE has offered the rights and licenses under this Agreement back to ENS by written notice and ENS has declined to accept such offer by written notice within ninety (90) days. In the event that ENS accepts the offer, the terms of this Agreement apply and regarding the transfer of data Sections 13.1.3., 13.1.4. and 13.1. 5. shall apply mutatis mutandis.
Termination by Roche without Cause After the Effective Date After the Effective Date, Roche shall have the right to terminate this Agreement at any time as a whole or on a Product-by-Product or country-by-country basis upon ninety (90) days prior written notice before First Commercial Sale in the Territory or upon one hundred eighty (180) days prior written notice after the First Commercial Sale in the Territory. The effective date of termination under this Section 18.2.2 shall be the date ninety (90) days (or one hundred eighty (180) days as the case may be) after Roche provides such written notice to Eleven.
Termination by Roche for Breach by Pieris or Pieris’ Insolvency Upon any termination by Roche for breach by Pieris or Pieris’ Insolvency, Roche and its Affiliates may upon notice retain all rights and licenses granted to Roche by Pieris under this Agreement; provided that after the effective date of termination the amounts of such payments and royalties that otherwise would have become due and payable shall continue to be due and payable to Pieris or its successor in interest (as applicable).
Termination by Roche. Roche shall have the right to terminate this Agreement as a whole, or on a Product-by- Product and/or country-by-country basis, for any reason or for no reason at any time, upon ninety (90) days’ prior written notice to Emisphere. If Roche terminates this Agreement with respect to a particular Product or country, then the licenses granted to Roche under Sections 5.1(a)(i) and 5.1(a)(ii), if then in effect, shall automatically
Termination by Roche without cause after the Research Term If Roche terminates this Agreement after the Research Term for no cause in application of Section 15.2.4, then:
Termination by Roche. Roche shall have the right, upon written notice to Biosite, to terminate Section 3.1(b) and the releases granted to Biosite and its Related Parties pursuant to Section 5.1 above if Biosite (a) directly or indirectly (whether alone, or in concert with or for the benefit of any third party) challenges, opposes, seeks to invalidate or render void or unenforceable all or a portion of the Roche Patent Rights (or purports to do any of the foregoing), through a declaratory judgment, provoking or supporting an interference action, or any other action or proceeding, or otherwise lends assistance to a third party to do any of the foregoing, except to the extent required by applicable law, regulation, court order or bona fide judicial process, or (b) attempts to enforce the Biosite Patent Rights against any Roche entity that is party to this Agreement or any of their respective Affiliates. If Roche terminates Sections 3.1(b) or 5.1 pursuant to this Section 8.3, the remainder of this Agreement shall remain in full force and effect in accordance with its terms.
Termination by Roche. (a) At the end of a two-(2)-year-period from the beginning of the Research Program Roche shall have the option to terminate the Research Program by giving six (6) months prior written notice to Helicon. In addition, if the milestones set forth in Section 6.8.4 have not been achieved by Helicon for reasons not attributable to Roche, then Roche shall have the right to terminate the Agreement by giving ninety (90) days prior written notice.
Termination by Roche. (a) Roche shall have the right to terminate this Agreement in its entirety for any reason or for no reason at any time after the expiration of the Research Term upon 60 days’ prior written notice to Metabasis. *** Confidential Treatment Requested
Termination by Roche. Roche may terminate this Agreement upon ninety (90) days written notice to PDL; however, any such termination prior to the end of the initial two-year term of the Research Program shall not relieve Roche of its obligations under Section 6.04 to make quarterly payments to PDL for the full two-year period provided in Section 6.01.
Termination by Roche. Roche may terminate this Agreement for any or no reason upon ninety (90) days prior written notice to Prothena.
